{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:47:22Z","timestamp":1792734442140,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40262-015-0343-6","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T08:12:04Z","timestamp":1448266324000},"page":"657-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics"],"prefix":"10.1007","volume":"55","author":[{"given":"Lisbeth V.","family":"Jacobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette K.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen H.","family":"Ingwersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,23]]},"reference":[{"key":"343_CR1","unstructured":"International Diabetes Federation. Diabetes atlas: sixth edition. 2014 update. http:\/\/www.idf.org\/diabetesatlas . Accessed 24 Sep 2015."},{"key":"343_CR2","unstructured":"International Diabetes Federation. About diabetes. https:\/\/www.idf.org\/about-diabetes . Accessed 23 Sep 2015."},{"key":"343_CR3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","volume":"55","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577\u201396.","journal-title":"Diabetologia"},{"key":"343_CR4","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/2047487312449414","volume":"20","author":"MP Hermans","year":"2013","unstructured":"Hermans MP, Brotons C, Elisaf M, Michel G, Muls E, Nobels F, et al. Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. Eur J Prev Cardiol. 2013;20:1095\u2013105.","journal-title":"Eur J Prev Cardiol."},{"key":"343_CR5","unstructured":"International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2012. http:\/\/www.idf.org\/sites\/default\/files\/IDF-Guideline-for-Type-2-Diabetes.pdf . Accessed 23 Sep 2015."},{"key":"343_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39\u201347.","journal-title":"Lancet"},{"key":"343_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","volume":"381","author":"JB Buse","year":"2013","unstructured":"Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117\u201324.","journal-title":"Lancet"},{"key":"343_CR8","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","volume":"384","author":"KM Dungan","year":"2014","unstructured":"Dungan KM, Povedano ST, Forst T, Gonz\u00e1lez JG, Atisso C, Sealls W, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349\u201357.","journal-title":"Lancet"},{"key":"343_CR9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","volume":"2","author":"RE Pratley","year":"2014","unstructured":"Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289\u201397.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"343_CR10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"A Garber","year":"2009","unstructured":"Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473\u201381.","journal-title":"Lancet"},{"key":"343_CR11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","volume":"26","author":"M Marre","year":"2009","unstructured":"Marre M, Shaw J, Br\u00e4ndle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26\u00a0weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268\u201378.","journal-title":"Diabet Med"},{"key":"343_CR12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84\u201390.","journal-title":"Diabetes Care"},{"key":"343_CR13","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","volume":"52","author":"D Russell-Jones","year":"2009","unstructured":"Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met\u00a0+\u00a0SU): a randomised controlled trial. Diabetologia. 2009;52:2046\u201355.","journal-title":"Diabetologia"},{"key":"343_CR14","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","volume":"32","author":"B Zinman","year":"2009","unstructured":"Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met\u00a0+\u00a0TZD). Diabetes Care. 2009;32:1224\u201330.","journal-title":"Diabetes Care"},{"key":"343_CR15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1463-1326.2011.01523.x","volume":"14","author":"AH Barnett","year":"2012","unstructured":"Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2012;14:304\u201314.","journal-title":"Diabetes Obes Metab"},{"key":"343_CR16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/dom.12262","volume":"16","author":"C Mathieu","year":"2014","unstructured":"Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014;16:636\u201344.","journal-title":"Diabetes Obes Metab"},{"key":"343_CR17","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s40265-014-0321-6","volume":"74","author":"LJ Scott","year":"2014","unstructured":"Scott LJ. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. Drugs. 2014;74:2161\u201374.","journal-title":"Drugs."},{"key":"343_CR18","unstructured":"Victoza\u00ae. Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022341lbl.pdf . Accessed 24 Sep 2015."},{"key":"343_CR19","unstructured":"Victoza\u00ae. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001026\/WC500050017.pdf . Accessed 24 Sep 2015."},{"issue":"12 Pt 2","key":"343_CR20","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1592\/phco.29.pt2.33S","volume":"29","author":"J Meece","year":"2009","unstructured":"Meece J. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog. Pharmacotherapy. 2009;29(12 Pt 2):33S\u201342S.","journal-title":"Pharmacotherapy."},{"key":"343_CR21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/VHRM.S4039","volume":"5","author":"CF Deacon","year":"2009","unstructured":"Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag. 2009;5:199\u2013211.","journal-title":"Vasc Health Risk Manag."},{"key":"343_CR22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"MA Nauck","year":"1993","unstructured":"Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741\u20134.","journal-title":"Diabetologia"},{"key":"343_CR23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s001250050664","volume":"40","author":"J Rachman","year":"1997","unstructured":"Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205\u201311.","journal-title":"Diabetologia"},{"key":"343_CR24","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1139\/y90-239","volume":"68","author":"C Ruiz-Grande","year":"1990","unstructured":"Ruiz-Grande C, Pintado J, Alarc\u00f3n C, Castilla C, Valverde I, L\u00f3pez-Novoa JM. Renal catabolism of human glucagon-like peptides 1 and 2. Can J Physiol Pharmacol. 1990;68:1568\u201373.","journal-title":"Can J Physiol Pharmacol"},{"key":"343_CR25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1055\/s-2007-1002190","volume":"25","author":"C Ruiz-Grande","year":"1993","unstructured":"Ruiz-Grande C, Alarc\u00f3n C, Alc\u00e1ntara A, Castilla C, L\u00f3pez Novoa JM, Villanueva-Pe\u00f1acarrillo ML, et al. Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res. 1993;25:612\u20136.","journal-title":"Horm Metab Res"},{"key":"343_CR26","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","volume":"44","author":"CF Deacon","year":"1995","unstructured":"Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126\u201331.","journal-title":"Diabetes"},{"key":"343_CR27","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","volume":"48","author":"A Plamboeck","year":"2005","unstructured":"Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48:1882\u201390.","journal-title":"Diabetologia"},{"key":"343_CR28","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/jc.2010-2822","volume":"96","author":"JB Buse","year":"2011","unstructured":"Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videb\u00e6k N, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011;96:1695\u2013702.","journal-title":"J Clin Endocrinol Metab"},{"key":"343_CR29","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/jps.23648","volume":"102","author":"A Plum","year":"2013","unstructured":"Plum A, Jensen LB, Kristensen JB. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis. J Pharm Sci. 2013;102:2882\u20138.","journal-title":"J Pharm Sci"},{"key":"343_CR30","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","volume":"43","author":"LB Knudsen","year":"2000","unstructured":"Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43:1664\u20139.","journal-title":"J Med Chem"},{"key":"343_CR31","unstructured":"Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analog, liraglutide. Presented at the 68th Scientific Sessions of the American Diabetes Association. San Francisco, CA, 6\u201310 Jun 2008."},{"key":"343_CR32","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1124\/dmd.110.034066","volume":"38","author":"M Malm-Erjef\u00e4lt","year":"2010","unstructured":"Malm-Erjef\u00e4lt M, Bj\u00f8rnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38:1944\u201353.","journal-title":"Drug Metab Dispos"},{"key":"343_CR33","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1177\/0091270011430504","volume":"52","author":"SH Ingwersen","year":"2012","unstructured":"Ingwersen SH, Khurana M, Madabushi R, Watson E, Jonker DM, Le Thi TD, et al. Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment. J Clin Pharmacol. 2012;52:1815\u201323.","journal-title":"J Clin Pharmacol"},{"key":"343_CR34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1463-1326.2010.01323.x","volume":"13","author":"W Yang","year":"2011","unstructured":"Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab. 2011;13:81\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"343_CR35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.diabres.2015.01.001","volume":"108","author":"SH Ingwersen","year":"2015","unstructured":"Ingwersen SH, Petri K, Tandon N, Yoon KH, Chen L, Vora J, et al. Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with type 2 diabetes from China, India and South Korea. Diabetes Res Clin Pract. 2015;108:113\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"343_CR36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","volume":"45","author":"H Agers\u00f8","year":"2002","unstructured":"Agers\u00f8 H, Jensen LB, Elbr\u00f8nd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195\u2013202.","journal-title":"Diabetologia"},{"key":"343_CR37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0091270006288215","volume":"46","author":"B Damholt","year":"2006","unstructured":"Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006;46:635\u201341.","journal-title":"J Clin Pharmacol"},{"key":"343_CR38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03762.x","volume":"70","author":"A Flint","year":"2010","unstructured":"Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol. 2010;70:807\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"343_CR39","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12133","volume":"15","author":"K Hermansen","year":"2013","unstructured":"Hermansen K, B\u00e6kdal TA, D\u00fcring M, Pietraszek A, Mortensen LS, J\u00f8rgensen H, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013;15:1040\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"343_CR40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5414\/CPP46273","volume":"46","author":"S Irie","year":"2008","unstructured":"Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther. 2008;46:273\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"343_CR41","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2009.03536.x","volume":"68","author":"LV Jacobsen","year":"2009","unstructured":"Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68:898\u2013905.","journal-title":"Br J Clin Pharmacol"},{"key":"343_CR42","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1177\/0091270010389468","volume":"51","author":"J Jiang","year":"2011","unstructured":"Jiang J, Zhang J, Jacobsen LV, Hu P. The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects. J Clin Pharmacol. 2011;51:1620\u20137.","journal-title":"J Clin Pharmacol"},{"key":"343_CR43","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270010374474","volume":"51","author":"C Kapitza","year":"2011","unstructured":"Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. J Clin Pharmacol. 2011;51:951\u20135.","journal-title":"J Clin Pharmacol"},{"key":"343_CR44","author":"M Malm-Erjef\u00e4lt","year":"2015","unstructured":"Malm-Erjef\u00e4lt M, Ekblom M, Vouis J, Zdravkovic M, Lennernas H. Effect on the gastrointestinal absorption of drugs from different classes in the biopharmaceutics classification system, when treating with liraglutide. Mol Pharm. 2015;. doi: 10.1021\/acs.molpharmaceut.5b00278 .","journal-title":"Mol Pharm"},{"key":"343_CR45","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.2337\/diacare.25.8.1398","volume":"25","author":"B Elbr\u00f8nd","year":"2002","unstructured":"Elbr\u00f8nd B, Jakobsen G, Larsen S, Agers\u00f8 H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002;25:1398\u2013404.","journal-title":"Diabetes Care"},{"key":"343_CR46","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1177\/0091270009354996","volume":"50","author":"E Watson","year":"2010","unstructured":"Watson E, Jonker DM, Jacobsen LV, Ingwersen SH. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol. 2010;50:886\u201394.","journal-title":"J Clin Pharmacol"},{"key":"343_CR47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40262-014-0229-z","volume":"54","author":"KC Petri","year":"2015","unstructured":"Petri KC, Jacobsen LV, Klein DJ. Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis. Clin Pharmacokinet. 2015;54:663\u201370.","journal-title":"Clin Pharmacokinet"},{"key":"343_CR48","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/dia.2013.0366","volume":"16","author":"DJ Klein","year":"2014","unstructured":"Klein DJ, Battelino T, Chatterjee DJ, Jacobsen LV, Hale PM, Arslanian S, et al. Liraglutide\u2019s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther. 2014;16:679\u201387.","journal-title":"Diabetes Technol Ther."},{"key":"343_CR49","unstructured":"Davies MJ, Atkin S, Bain SC, Rossing P, Scott D, Shamkhalova M, et al. Efficacy and safety of liraglutide versus placebo as add-on to existing diabetes medication in subjects with type 2 diabetes (T2DM) and moderate renal impairment (LIRA-RENAL). Presented at the American Diabetes Association, 74th Annual Scientific Sessions, San Francisco, CA, 13\u201317 June 2014."},{"issue":"12","key":"343_CR50","doi-asserted-by":"crossref","first-page":"e113468","DOI":"10.1371\/journal.pone.0113468","volume":"9","author":"T Osonoi","year":"2014","unstructured":"Osonoi T, Saito M, Tamasawa A, Ishida H, Tsujino D, Nishimura R, et al. Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study. PLoS ONE. 2014;9(12):e113468.","journal-title":"PLoS ONE"},{"key":"343_CR51","author":"T Idorn","year":"2015","unstructured":"Idorn T, Knop FK, J\u00f8rgensen MB, Jensen T, Resuli M, Hansen PM, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blinded, parallel group, randomized trial. Diabetes Care. 2015;. doi: 10.2337\/dc15-1025 .","journal-title":"Diabetes Care"},{"key":"343_CR52","unstructured":"US Food and Drug Administration. The Biopharmaceutics Classification System (BCS) Guidance. January 2009. www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm128219.htm . Accessed 24 Sep 2015."},{"key":"343_CR53","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1177\/0091270010389471","volume":"51","author":"LV Jacobsen","year":"2011","unstructured":"Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with liraglutide, a once-daily GLP-1 analog, does not reduce the bioavailability of ethinyl estradiol\/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol. 2011;51:1696\u2013703.","journal-title":"J Clin Pharmacol"},{"key":"343_CR54","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s12325-011-0044-y","volume":"28","author":"C Kapitza","year":"2011","unstructured":"Kapitza C, Zdravkovic M, Hindsberger C, Flint A. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Adv Ther. 2011;28:650\u201360.","journal-title":"Adv Ther."},{"key":"343_CR55","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc11-1928","volume":"35","author":"JH DeVries","year":"2012","unstructured":"DeVries JH, Bain SC, Rodbard HW, Seufert J, D\u2019Alessio D, Thomsen AB, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35:1446\u201354.","journal-title":"Diabetes Care"},{"key":"343_CR56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1463-1326.2010.01322.x","volume":"13","author":"L Morrow","year":"2011","unstructured":"Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab. 2011;13:75\u201380.","journal-title":"Diabetes Obes Metab"},{"key":"343_CR57","author":"C Kapitza","year":"2015","unstructured":"Kapitza C, Bode B, Ingwersen SH, Jacobsen LV, Poulsen P. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. J Clin Pharmacol. 2015;. doi: 10.1002\/jcph.549 .","journal-title":"J Clin Pharmacol"},{"key":"343_CR58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/diabetes.51.2.424","volume":"51","author":"CB Juhl","year":"2002","unstructured":"Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agers\u00f8 H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51:424\u20139.","journal-title":"Diabetes"},{"key":"343_CR59","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2337\/diabetes.52.7.1786","volume":"52","author":"AM Chang","year":"2003","unstructured":"Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003;52:1786\u201391.","journal-title":"Diabetes"},{"key":"343_CR60","unstructured":"Nauck MA, El-Ouaghlidi A, Hompesch M, Jacobsen J, Elbr\u00f8nd B. No impairment of hypoglycaemic counterregulation via glucagon with the long-acting GLP-1 derivative, NN2211 (liraglutide), in subjects with type 2 diabetes. Presented at the 18th International Diabetes Federation Congress. Paris, France, 24\u201329 August 2003."},{"key":"343_CR61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12325-010-0110-x","volume":"28","author":"A Flint","year":"2011","unstructured":"Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011;28:213\u201326.","journal-title":"Adv Ther."},{"key":"343_CR62","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","volume":"97","author":"M Horowitz","year":"2012","unstructured":"Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97:258\u201366.","journal-title":"Diabetes Res Clin Pract"},{"key":"343_CR63","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","volume":"25","author":"T Vilsb\u00f8ll","year":"2008","unstructured":"Vilsb\u00f8ll T, Brock B, Perrild H, Levin K, Lervang H-H, K\u00f8lendorf K, et al. Liraglutide, a once-daily human GLP-1 analogue improves beta-cell function and arginine stimulated insulin secretion at hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008;25:152\u20136.","journal-title":"Diabet Med"},{"key":"343_CR64","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","volume":"11","author":"J Jendle","year":"2009","unstructured":"Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, D\u00fcring M, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163\u201372.","journal-title":"Diabetes Obes Metab"},{"key":"343_CR65","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dom.12108","volume":"15","author":"A Flint","year":"2013","unstructured":"Flint A, Kapitza C, Zdravkovic M. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Diabetes Obes Metab. 2013;15:958\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"343_CR66","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","volume":"53","author":"KB Degn","year":"2004","unstructured":"Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week\u2019s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187\u201394.","journal-title":"Diabetes"},{"key":"343_CR67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2796.1999.00548.x","volume":"246","author":"F Karpe","year":"1999","unstructured":"Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med. 1999;246:341\u201355.","journal-title":"J Intern Med"},{"key":"343_CR68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1900\/RDS.2004.1.175","volume":"1","author":"M Carstensen","year":"2004","unstructured":"Carstensen M, Thomsen C, Gotzsche O, Holst JJ, Schrezenmeir J, Hermansen K. Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction. Rev Diabet Stud. 2004;1:175\u201384.","journal-title":"Rev Diabet Stud."},{"key":"343_CR69","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","volume":"298","author":"BG Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299\u2013308.","journal-title":"JAMA"},{"key":"343_CR70","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00125-005-0126-y","volume":"49","author":"JJ Meier","year":"2006","unstructured":"Meier JJ, Gethmann A, G\u00f6tze O, Gallwitz B, Holst JJ, Schmidt WE, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49:452\u20138.","journal-title":"Diabetologia"},{"key":"343_CR71","doi-asserted-by":"crossref","first-page":"279530","DOI":"10.1155\/2011\/279530","volume":"2011","author":"CS Marathe","year":"2011","unstructured":"Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011;2011:279530.","journal-title":"Exp Diabetes Res."},{"key":"343_CR72","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0091270004274432","volume":"45","author":"E Blase","year":"2005","unstructured":"Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol. 2005;45:570\u20137.","journal-title":"J Clin Pharmacol"},{"key":"343_CR73","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1080\/00365520701370922","volume":"42","author":"H Glerup","year":"2007","unstructured":"Glerup H, Bluhme H, Villadsen GE, Rasmussen K, Ejskjaer N, Dahlerup JF. Gastric emptying: a comparison of three methods. Scand J Gastroenterol. 2007;42:1182\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"343_CR74","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003088-199427060-00004","volume":"27","author":"JM Greiff","year":"1994","unstructured":"Greiff JM, Rowbotham D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet. 1994;27:447\u201361.","journal-title":"Clin Pharmacokinet"},{"key":"343_CR75","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1023\/A:1011935603893","volume":"46","author":"M Willems","year":"2001","unstructured":"Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci. 2001;46:2256\u201362.","journal-title":"Dig Dis Sci"},{"key":"343_CR76","unstructured":"Flint A, Hindsberger C. The relationship between pharmacokinetics of the once-daily human GLP-1 analog liraglutide and pharmacodynamic effects on glycemia, gastric emptying, and energy intake. Presented at the American Diabetes Association, 70th Annual Scientific Sessions. Orlando, FL, 25\u201329 June 2010."},{"key":"343_CR77","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/0016-5085(93)90640-X","volume":"104","author":"YF Ghoos","year":"1993","unstructured":"Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, et al. Measurement of gastric emptying rate of solids by means of carbon-labelled octanoic acid breath test. Gastroenterology. 1993;104:1640\u20137.","journal-title":"Gastroenterology"},{"key":"343_CR78","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1079\/BJN19890116","volume":"61","author":"KM Cunningham","year":"1989","unstructured":"Cunningham KM, Read NW. The effect of incorporating fat into different components of a meal on gastric emptying and postprandial blood glucose and insulin responses. Br J Nutr. 1989;61:285\u201390.","journal-title":"Br J Nutr"},{"key":"343_CR79","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728\u201342.","journal-title":"Nat Rev Endocrinol."},{"key":"343_CR80","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1463-1326.2012.01557.x","volume":"14","author":"J Jelsing","year":"2012","unstructured":"Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB. Liraglutide: short-lived effect on gastric emptying: long lasting effects on body weight. Diabetes Obes Metab. 2012;14:531\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"343_CR81","first-page":"42","volume":"15","author":"K Niswender","year":"2013","unstructured":"Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes ObesMetab. 2013;15:42\u201354.","journal-title":"Diabetes ObesMetab."},{"key":"343_CR82","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1210\/jc.2015-1176","volume":"100","author":"EW Iepsen","year":"2015","unstructured":"Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, J\u00f8rgensen NR, et al. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab. 2015;100:2909\u201317.","journal-title":"J Clin Endocrinol Metab"},{"key":"343_CR83","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/0091270009339189","volume":"49","author":"DJ Chatterjee","year":"2009","unstructured":"Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol. 2009;49:1353\u201362.","journal-title":"J Clin Pharmacol"},{"key":"343_CR84","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1463-1326.2012.01576.x","volume":"14","author":"SCL Gough","year":"2012","unstructured":"Gough SCL. Liraglutide: from clinical trials to clinical practice. Diabetes Obes Metab. 2012;14:33\u201340.","journal-title":"Diabetes Obes Metab"},{"key":"343_CR85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00418343","volume":"39","author":"J Markussen","year":"1996","unstructured":"Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstr\u00f8m J, Hasselager E, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia. 1996;39:281\u20138.","journal-title":"Diabetologia"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0343-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-015-0343-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0343-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:06:51Z","timestamp":1553612811000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-015-0343-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,23]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1007\/s40262-015-0343-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,23]]}}}